Should You Buy NuScale Power While It's Below $50?

NuScale Power has surged more than 20% over the past 30 days, but remains down about 77% from its all-time high last October, with a market cap near $4.3 billion. The article is constructive on the long-term $10 trillion nuclear opportunity and SMR adoption, but stresses two key risks: delayed commercialization, with NuScale’s first system not expected until around 2032, and elevated volatility across SMR stocks. The near-term message is bullish on the sector’s potential but cautious on timing and execution.

Analysis

The market is still pricing SMR as a near-term construction story, but the real optionality is in licensing credibility and capital formation, not first revenue. That makes the opportunity path-dependent: every incremental regulatory approval, utility partnership, or government subsidy can rerate the stock violently even if cash flows remain years away. In that framework, the largest winners may not be the first movers alone, but also the equipment, engineering, and uranium supply chain names that monetize nuclear normalization earlier than reactor vendors.

The second-order risk is that long-duration project equity gets punished as rates stay elevated and investors lose patience. If deployment slips from the early 2030s toward the mid-2030s, the market will compress terminal value assumptions faster than operating milestones can offset them, which is why SMR names behave more like venture capital than infrastructure. That dynamic also creates a skewed volatility surface: upside gaps on policy/newsflow, but repeated drawdowns on any schedule slip or financing headline.

The contrarian view is that the current narrative may be underestimating how long it takes for AI/data-center demand to translate into signed, financeable nuclear contracts. Utilities and hyperscalers are likely to prefer shorter-cycle power solutions first, so SMR adoption could be more of a 2030s call option than a 2020s earnings driver. If that’s right, the trade is less about buying equity beta here and more about structuring exposure around catalysts with defined downside.

Key Decisions for Investors

• Avoid outright long SMR at current levels; the risk/reward is poor until a harder de-risking event occurs (license, binding utility PPA, or project finance close). Treat as a tradeable catalyst stock, not a core position.
• For higher-conviction exposure, buy a basket of nuclear enablers rather than reactor developers: use long uranium/supply-chain proxies or nuclear equipment beneficiaries over the next 6-18 months to capture earlier monetization.
• If seeking upside convexity in SMR, use call spreads rather than stock: e.g., 12-18 month SMR call spreads sized small, with profit-taking into any approval or partnership announcement to avoid theta decay from the long timeline.
• Relative value: short SMR / long OKLO on strength only if you want to express dispersion around execution quality; otherwise stay flat because both names share the same duration/rate factor and can fall together on funding stress.
• Set a tactical buy trigger only on a post-news pullback of 15-20% after a legitimate catalyst; that improves entry versus chasing momentum in a name where cash flows remain years out.